Navigation Links
Starting HIV Drugs Earlier May Delay AIDS But Not Death
Date:4/18/2011

By Randy Dotinga
HealthDay Reporter

MONDAY, April 18 (HealthDay News) -- New research suggests that HIV-infected patients are most likely to stay clear of AIDS longer if they start drug therapy when their immune systems are still relatively strong.

However, starting treatment earlier, compared to waiting, didn't affect dying from AIDS.

"There wasn't a clear benefit in terms of preventing death" by prescribing the drugs before some guidelines suggest, said Dr. Keith Henry, director of HIV clinical research at Hennepin County Medical Center in Minneapolis and co-author of a commentary accompanying the study, published in the April 19 edition of Annals of Internal Medicine.

The issue of when to begin drug treatment is a hot topic in the field of AIDS/HIV medicine. If physicians wait to begin treatment, patients can delay the expense -- not to mention the side effects -- of pricey anti-HIV drugs. But such delays may also give the virus a chance to become more powerful and better able to fend off medications.

If they're not treated with drugs, HIV-infected people almost always go on to develop AIDS.

So when should doctors turn to the drugs? In the U.S., guidelines suggest that HIV-infected patients take them when the level of CD4 cells -- an important part of the immune system -- dips below 0.500 X 109 cells per liter (cells/L). In Europe, the guideline number is frequently lower -- meaning a weaker immune system -- at under 0.350 X 109 cells/L.

In the new study, researchers examined how patients did when they began drug therapy with their CD4 cells at a variety of levels.

The study authors examined the medical records of almost 21,000 HIV-infected patients who sought treatment in HIV clinics in Europe and through the Veterans Health Administration system in the United States. The researchers found that the death rate was about the same regardless of whether patients began treatment when their CD4 levels dipped under 0.500 X 109 cells/L or if they waited until their immune systems deteriorated more and reached below the level of 0.350 X 109 cells/L.

However, the risk of death did rise when patients weren't treated until their CD4 cells fell to an even lower level: 0.200 X 109 cells/L.

Patients were better able to stave off AIDS itself when they began treatment when their immune systems were stronger -- when they dipped below 0.500 X 109 cells/L.

In other words, starting treatment early -- when levels dip below 0.500 X 109 cells/L -- didn't seem to help patients live longer compared to starting it a bit later. But it did appear to keep AIDS from developing as quickly.

What to do?

"To fully benefit from early initiation, patients must present for medical care while their CD4 cell counts are still above 500 cells," said study lead author Lauren Cain, a research fellow at Harvard School of Public Health.

There are other issues to consider, added Henry, the commentary co-author. When it comes to available money for HIV/AIDS treatment, "the U.S. is actually a resource-poor country," Henry said, which makes it difficult to say that patients should always get the HIV drugs early. "You have to make some decisions about who you treat. In a perfect world maybe everybody should be treated. But guess what? It's not a perfect world," he added.

And in far too many cases, he said, "the decision is already made" -- patients don't go to get treated until it's too late to begin early therapy, anyway. That's because the levels of immune cells in their bodies have already dwindled too far.

More information

There's more on HIV/AIDS at the U.S. National Library of Medicine.

SOURCES: Keith Henry, M.D., director, HIV clinical research, Hennepin County Medical Center, Minneapolis; Lauren Cain, research fellow, department of epidemiology, Harvard School of Public Health, Boston; April 19, 2011, Annals of Internal Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Happy Feet Clinic Now Open in Buffalo Grove, IL; Starting A Business in Impossible Times: Valuable Insights and Experiences
2. French-Based Non-Profit AIDES is Starting a New Collaboration With Goodby, Silverstein & Partners
3. NursePractitionerBusinessOwner.com Announces No-Charge Teleseminar for Nurse Practitioners Interested in Starting Their Own Practice
4. 16.6 million small business employees could benefit from ACA provisions starting this year
5. Starting dialysis too early can increase risk of death
6. Starting School Early May Keep Girls Thin
7. With Hormone Therapy, Starting Later May Be Less Risky
8. Gender Gap in Starting Doctor Pay Grows
9. Starting periods before the age of 10 increases risk of lung complaints in future
10. The private sale of drugs in public hospitals
11. Social Anxiety and Panic - Alternative Treatment to Drugs and Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Starting HIV Drugs Earlier May Delay AIDS But Not Death
(Date:6/23/2016)... ... June 23, 2016 , ... Virginia Beach resident Sean Kelly ... turned towards the water to find peace and set out to accomplish a personal ... and turned to the internet. He came across the story of another special operations ...
(Date:6/23/2016)... ... 2016 , ... The annual Blue Ribbon Highlights Session took ... and Movement Disorders. This special session provides a critical review of the best ... of both clinical and basic research presented by delegates. , Of the ...
(Date:6/23/2016)... ... 2016 , ... The U.S. Supreme Court decision on immigration has significant consequences ... Senior Citizens League (TSCL) . “President Obama’s executive actions on immigration would have ... worked in this country illegally, even though the newly - issued green cards are ...
(Date:6/23/2016)... ... 23, 2016 , ... For the second time this year, ... Medical Education program, this time in pediatrics. The news from the Accreditation Council ... training that will begin in July 2017. ACGME had previously accredited Memorial’s Physical ...
(Date:6/23/2016)... Research Triangle Park, NC (PRWEB) , ... June 23, 2016 , ... ... Alzheimer’s disease, is announcing that the U.S. Food and Drug Administration (FDA) has granted ... T3D-959 in a limited number of subjects who completed the main Phase 2a study ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Bracket , a leading ... next generation clinical outcomes platform, Bracket eCOA (SM) 6.0, ... June 26 – 30, 2016 in Philadelphia ... Clinical Outcome Assessment product of its kind to fully integrate ... Bracket eCOA 6.0 is a flexible platform for electronic ...
(Date:6/23/2016)... 2016  Guerbet announced today that it has been ... Award . One of 12 suppliers to ... its support of Premier members through exceptional local customer ... commitment to lower costs. ... our outstanding customer service from Premier," says Massimo ...
(Date:6/23/2016)... June 23, 2016  The National Pharmaceutical Council ... the health policy research organization as its newest ... MD, senior vice president and chief scientific officer, ... on the NPC Board of Directors. ... Mallinckrodt has joined us in support of our ...
Breaking Medicine Technology: